Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2018 / Article

Review Article | Open Access

Volume 2018 |Article ID 6986984 | https://doi.org/10.1155/2018/6986984

Joseph Vamecq, Pierre Andreoletti, Riad El Kebbaj, Fatima-Ezzahra Saih, Norbert Latruffe, M’ Hammed Saïd El Kebbaj, Gérard Lizard, Boubker Nasser, Mustapha Cherkaoui-Malki, "Peroxisomal Acyl-CoA Oxidase Type 1: Anti-Inflammatory and Anti-Aging Properties with a Special Emphasis on Studies with LPS and Argan Oil as a Model Transposable to Aging", Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 6986984, 13 pages, 2018. https://doi.org/10.1155/2018/6986984

Peroxisomal Acyl-CoA Oxidase Type 1: Anti-Inflammatory and Anti-Aging Properties with a Special Emphasis on Studies with LPS and Argan Oil as a Model Transposable to Aging

Academic Editor: Javier Egea
Received29 Sep 2017
Accepted23 Jan 2018
Published25 Mar 2018


To clarify appropriateness of current claims for health and wellness virtues of argan oil, studies were conducted in inflammatory states. LPS induces inflammation with reduction of PGC1-α signaling and energy metabolism. Argan oil protected the liver against LPS toxicity and interestingly enough preservation of peroxisomal acyl-CoA oxidase type 1 (ACOX1) activity against depression by LPS. This model of LPS-driven toxicity circumvented by argan oil along with a key anti-inflammatory role attributed to ACOX1 has been here transposed to model aging. This view is consistent with known physiological role of ACOX1 in yielding precursors of specialized proresolving mediators (SPM) and with characteristics of aging and related disorders including reduced PGC1-α function and improvement by strategies rising ACOX1 (via hormonal gut FGF19 and nordihydroguaiaretic acid in metabolic syndrome and diabetes conditions) and SPM (neurodegenerative disorders, atherosclerosis, and stroke). Delay of aging to resolve inflammation results from altered production of SPM, SPM improving most aging disorders. The strategic metabolic place of ACOX1, upstream of SPM biosynthesis, along with ability of ACOX1 preservation/induction and SPM to improve aging-related disorders and known association of aging with drop in ACOX1 and SPM, all converge to conclude that ACOX1 represents a previously unsuspected and currently emerging antiaging protein.

1. Introduction

Vegetal compounds and oils are current trends for active research. One reason lies in the consideration that nature forms a whole and may provide living beings with both pathogenic and curative factors. Beside vegetal poisons [1], some vegetal compounds as for instance those extracted from Digitalis purpurea and Camptotheca acuminata tree may be therapeutically active [2, 3] or in turn may serve as guide compounds for medicinal chemistry design in cardiovascular disorders and cancer. It remains currently unclear whether, however, such real curative medical indications may be attributed as a general rule to the bulk of vegetal-derived compounds or oils endowed with health-improving properties. In this respect, argan oil is currently becoming largely acclaimed for a large variety of health and wellness virtues [4, 5]. The anti-inflammatory potential of argan oil has been recently addressed by evaluating its effects towards the highly inflammatory LPS using a murine model of sepsis [6]. In this disorder, peroxisomal Acyl-CoA oxidase 1 (ACOX1) was preserved by argan oil against inactivation by LPS in the same time as the oil protected the liver against most of LPS-driven toxicity and metabolic homeostasis disruption [6]. On the other hand, ACOX1 initiates the peroxisomal pathway ensuring retroconversion of polyunsaturated fatty acids [7]. Key role of ACOX1 in biosyntheses of eicosanoids (E series) and docosanoids (D series) further yielding specialized proresolving mediators (SPM) (resolvins, neuroprotectins, and maresins) [8, 9] is stressed along with preserved or increased ACOX1 activity in models of diabetes and metabolic syndromes. The alterations in SPM production and their roles as potential therapeutic candidates in many other pathological states linked to aging such as neurodegenerative disorders (e.g., Alzheimer’s disease), macular degeneration, and vascular disorders (stroke, atherosclerosis, and mitochondrial dysfunction in senescent brain) are further developed.

Olive oil contains about 70% oleic acid while argan oil harbors 45% oleic acid and 35% linoleic acid, indicating that argan oil is richer in polyunsaturated fatty acids [10]. Early studies on argan oil revealed its beneficial effects on lipid metabolism and antioxidant status through drops in plasma low density lipoprotein-cholesterol (LDL-cholesterol) and lipoperoxides, along with a rise in plasma tocopherol concentration [11]. In this respect, argan oil contains a high level of antioxidant compounds including gamma-tocopherol and also ferulic acid which exhibit ROS-scavenging and anti-inflammatory properties [12]. Cumulated activities of these individual argan oil components meet therapeutic efficacy in humans as attested by the beneficial metabolic effects of argan oil reported in several clinical trials on dyslipidemic markers [11]. Improvements of dyslipidemia by argan oil are consistent with studies on the expression of nuclear genes controlling lipid metabolism which, as highlighted in the next section, have shown in an animal model of human sepsis that argan oil upregulates hepatic expression of PGC-1α, leading to parallel coactivations of the nuclear receptors—PPARα, ERRα, and HNF-4α—which govern FAOx metabolism and gluconeogenesis [6].

2. Studies with Protection by Argan Oil of LPS-Induced Model of Sepsis

Chronic administration of argan oil prevents liver dysfunction experimentally induced by sepsis-mimicking conditions [6]. This result was obtained in mice exposed to LPS as a model for human sepsis. Preventive protection was observed at reasonable oil diet concentrations (6%), suggesting a potential applicability of this diet measure in the medical practice. This observation makes chronic argan oil intakes preventive antidotes for sepsis and, hence, might suggest influence of diet backgrounds of patients on sepsis development and prognosis. Whether therapeutic issues may ultimately emerge from administration of this oil, though promising, still remains speculative. Nonetheless, mechanisms by which its administration is capable of blunting sepsis LPS-driven liver dysfunction are remarkable and provide liver with a unique point-to-point reply to various signaling and metabolic targets of sepsis. The various ways altering the capacity of liver engine to fulfill energetic demands of extrahepatic tissues are subject to a suited protection through stimulation or preservation of signaling and metabolic events, which are extinct by sepsis (Figure 1). Part of features enabling LPS to disrupt signaling for liver metabolic support to extrahepatic tissues and prevention by argan oil [6] is illustrated in Figure 1 panels A and B, respectively. The depicted events have been arbitrarily divided in PGC1-α-dependent and independent features. LPS negatively impacts signaling for fatty acid oxidation and gluconeogenesis, the two key metabolic pathways enabling liver to aliment extrahepatic tissues in energetic substrates in periods of increased energy demands. PGC-1α-independent LPS features include sterol depletion by LPS leading to the LPS-dependent activation of SREBP1 [13], which in turn enhances gene expression of lipin-1 [14, 15]. The accumulation of diacylglycerol, which may involve lipin-1, leads to gluconeogenesis impairment through mTOR signaling [16] (Figure 1(a), left part). PGC-1α-dependent mechanisms mainly lie in a severe drop in PGC-1α signaling with resulting loss in PPARα and HNF-4α signaling (Figure 1(b), right part).

Under LPS, argan oil (Figure 1(b), right part) stimulates PPARα and PGC-1α signaling, contributing to stimulate fatty acid oxidation, and via the impact of PGC-1α acting as a coactivator of HNF-4α, to preserve gluconeogenesis despite no concomitant drop in lipin-1 signaling by this oil [6]. Under LPS, depression of lipin-1 by olive oil (Figure 1(b), left part) would avoid a negative impact on gluconeogenesis signaling. By contrast to argan oil, olive oil does not fully rescue the LPS-decreased PGC-1α expression. So, this may prevent the lowering of fatty acid oxidation activity and allows its preservation under exposure to LPS [6]. Figure 2 illustrates that argan and olive oils preserve normal hepatic fatty acid oxidation and gluconeogenesis capacities under LPS. Under LPS, each of the pathologically disrupted steps is preserved under chronic administration of the oils. As highlighted by the figure, oils may be considered as affording a protection highly adapted to the metabolically toxic liver changes induced by LPS.

3. Transposing to Aging the Sepsis Model of Inflammation Induced by LPS and Resolved by Argan Oil

The liver metabolic changes and underlying signaling characterizing LPS-induced model of sepsis and counteraction by argan oil have been mentioned and illustrated above. What has been illustrated in Figures 1 and 2 is essentially how the major liver energetic metabolic pathways (gluconeogenesis, mitochondrial fatty acid oxidation) and underlying signaling are modified by LPS and under LPS how argan oil may impact LPS-induced changes. Effects on peroxisomal β-oxidation, which is not per se an energetic pathway, have not been depicted in these figures. Interestingly enough, one of the toxic effects of LPS on mouse liver metabolism was a significant drop in acyl-CoA oxidase 1 activity [6]. LPS-mediated inhibition of peroxisomal β-oxidation activity was also described in rat liver under experiments focusing on the effect of endotoxin treatment on peroxisomal β-oxidation enzymology [17]. In this study, peroxisomal β-oxidation measured as lignoceric oxidation rates and ACOX1 activity was reduced to 56 and 73% control values, respectively [14]. Argan oil prevented LPS-induced drop of the ACOX1 activity in liver from mice exposed to LPS [6].

Figure 3 is an attempt to model LPS-driven toxicity and protective effect of argan oil with a special emphasis on ACOX1. This representation is interesting because it attributes a key role to ACOX1 in controlling inflammation in a way upstream of the metabolic reprogramming induced by LPS. This reprogramming of energetic metabolism by LPS has been shown to involve depression of PGC-1α activity [10, 18]. In our representation appearing in Figure 3(a), this reprogramming of energetic metabolism is induced by inflammation and leads to impairment of ACOX1 explaining that protection (by argan oil) of this enzyme might restore an active control of inflammation and hence a unique opportunity to remove the energy metabolic reprogramming responsible for toxicity (by LPS). In our previous study on mouse model for sepsis, LPS induced a deep drop in PGC-1α; argan oil effectively protected ACOX1 and removed energy metabolic reprogramming as attested by full restitution of PGC-1α [6].

A remarkable feature is the appropriateness to transpose to aging our model of LPS-driven toxicity and protective effect of argan oil with a special emphasis on ACOX1. This is done and illustrated in Figure 3(b). Like LPS, aging promotes inflammation. It is well accepted that aging is characterized by a delay to resolve inflammation [19]. Another extraordinary parallelism between LPS and aging is the drop in PGC-1α, along with sometimes rescue by a rise in PGC-1α, which has been observed and incriminated in aging [20] and the development of many aging-related disorders including obesity and type 2 diabetes [21, 22], coronary diseases [23], neurodegenerative disorders (Alzheimer [24, 25], Parkinson [2628], and Huntington [2931] diseases), myocardial infarction [3237], mitochondrial dysfunction in senescent brain [20, 38, 39], and stroke [4043].

Consistent also with the relevance of the emerging model of aging appearing on Figure 3 are as developed thereafter (i) the remarkable anti-inflammatory potential of ACOX1 through generation of precursors of lipid mediators with potent anti-inflammatory activity (specialized proresolving mediators, SPM), (ii) protection given by either argan oil use or ACOX1 induction in signaling pathways improving diabetes and metabolic syndromes and (iii) protection given by SPM in age-related disorders.

4. Studies Highlighting that ACOX1 Is Physiologically Involved in the Synthesis of Precursors of Specialized Proresolving Mediators (SPM)

4.1. Peroxisomal Acyl-CoA Oxidase 1 in Health and Disease
4.1.1. LPS Reduces Liver ACOX1 in a Way Counteracted by Oils

One of the toxic effects of LPS on liver metabolism was a significant drop in acyl-CoA oxidase 1 activity [6]. One of the putative protective effects of oils, argan and to a lesser extent olive oil, is prevention of LPS-induced drop in the expression of the peroxisomal protein [6].

4.1.2. ACOX 1 in the Physiology of Peroxisomal β-Oxidation

Acyl-CoA oxidase 1 (ACOX1) belongs to one of the two separate β-oxidation systems identified in peroxisomes [44]. In the first peroxisomal β-oxidation system, ACOX1 catalyzes the first and the rate-limiting step of straight-chain fatty acids [45]. In contrast, structurally unrelated acyl-CoA oxidases 2 and 3, of the second peroxisomal β-oxidation system, metabolize branched-chain fatty acids (pristanic acid) and C27 bile acid precursors, respectively, although in the humans type 2 is the only acyl-CoA oxidase involved in bile acid biosynthesis, and both type 2 and 3 acyl-CoA oxidases are functional on branched-chain fatty acyl-CoA [44, 46].

4.1.3. Anti-Inflammatory Potential of ACOX 1

ACOX1, one of the targets of LPS [6], has proven anti-inflammatory properties and, in the context of sepsis, its preservation by oils, under signaling adaptations abundantly developed above, might contribute to liver protection. Anti-inflammatory action of ACOX1 is based on various pathogenesis and physiological pieces of evidence considered thereafter.

(1) ACOX1 Null Mice. Mice lacking ACOX1 manifest severe inflammatory steatohepatitis with increased intrahepatic H2O2 levels and hepatocellular regeneration [47]. This hepatic oxidative stress may trigger TNFα production by Kupffer cells. Progressively, chronic endoplasmic reticulum stress contributes to hepatocarcinogenesis [48] and this steatotic ACOX1 null phenotype can be reversed by expression of the human ACOX1 [48, 49]. In the ACOX1-dependent hepatocarcinogenesis, the involvement of nuclear receptor PPARα is essential [50]. In brain lesions of patients with peroxisomal β-oxidation deficit, oxidative, inflammatory, and apoptotic processes have been described [51]. The expressions of genes coding for cytokines IL-6, IL-8, and TNFα, which are typically produced by macrophages and by CD4+ T cells Th1, have also been found to be increased in ACOX1 deficiency [52]. On the other hand, several cytokines and chemokine mRNAs are strongly downregulated in ACOX1-deficient patient fibroblasts, including CXCL14 and CXCL12 genes, which have been shown to participate in the regulation of cell or tissue homeostasis [52]. In this peroxisomal disorder, lipid derivatives with an abnormally high proportion of VLCFA residues have been proposed to trigger the initial cascade of the inflammatory process [53]. The severity of the metabolic disruption associated with peroxisomal ACOX1 deficiency underlines the crucial role of peroxisomes in synthesizing or degrading highly specific metabolites, accumulation or deficit of which may impact peroxisome biogenesis itself and/or collaborative working with other cellular organelles such as mitochondria and endoplasmic reticulum.

(2) Physiological Role of ACOX1 in the Metabolism of Polyunsaturated Fatty Acids (PUFA). Physiological evidence for a key role of ACOX1 in alimenting docosanoid formation (for metabolic steps, elongases and desaturases, of PUFA synthesis considered throughout the text thereafter (see [54]) rests on the key role of this enzyme in the retroconversion of polyunsaturated fatty acids (PUFAs) (Figure 4) [7, 5459]. For recall, families of PUFAs are characterized by the position of the unsaturation closest to the terminal, so-called ω, methyl of the fatty acid carbon chain. In contrast to the position of the unsaturation towards the carboxylate, that towards the other end of the carbon chain is kept upon elongation or shortening of the carbon chain. Among these families, the ω-6 and ω-3 families are generated from linoleic and α-linolenic acids, respectively. The metabolism of these PUFAs is illustrated on Figure 4 and starts with their preliminary activation into CoA esters by acyl-CoA synthetases prior to handling by acyl-CoA desaturases and elongases.

5. PUFA Desaturases and Elongases

Acyl-CoA desaturases introduce cis-double bonds between the carboxylate group and the first unsaturation of the carbon chain, at three carbons from this unsaturation. The desaturase(s) acting on C18 and C24 PUFAs is a Δ6-desaturase and that acting on the C20 PUFAs is a Δ5-desaturase. The latter desaturase produces CoA esters of arachidonic acid or ARA (5,8,11,14-eicosatetraenoic acid) and EPA (5,8,11,14,17-eicosapentaenoic acid). Nonesterified forms of PUFAs are released from phospholipids by PLA2. They are substrates for cyclooxygenases and lipooxygenases, which drive the C20 PUFAs (eicosanoids) towards prostanoids (prostaglandins and thromboxanes) and leukotrienes (plus HPETE, hydroperoxyeicosatetraenoic acids, and HETE, hydroxyeicosatetraenoic acids) syntheses, respectively [6062]. CoA esters of ARA and EPA not having been incorporated into phospholipids may continue elongation.

6. PUFA Retroconversion

Though this view has been recently seriously challenged (see consideration below in the text), mammalian cells are assumed to possess little or no direct PUFA Δ4-desaturase activity, so the ARA-CoA and EPA-CoA elongation products in C22 (7,10,13,16-docosatetraenoyl-CoA [ω6] and 7,20,13,16,19-docosapentaenoyl-CoA [ω3]) would not be immediately desaturated at the Δ4 position. In order to produce the corresponding Δ4-desaturated metabolites, cells are capable of operating an additional elongation converting C22 (7,10,13,16-docosatetraenoyl-CoA [ω6] and 7,20,13,16,19-docosapentaenoyl-CoA [ω3]) to C24 (9,12,15,18-tetracosatetraenoyl-CoA [ω6] and 9,12,15,18,21-tetracosapentaenoyl-CoA [ω3]) products. As mentioned above, these C24 PUFAs are substrates for Δ6 desaturase. The C24 products desaturated in Δ6 (6,9,12,15,18-tetracosapentaenoyl-CoA [ω6] and 6,9,12,15,18,21-tetracosahexaenoyl-CoA [ω3]) may undergo a two-carbon chain shortening which generates C22 PUFAs now presenting with an unsaturation at the Δ4 position. So, cells may catalyze Δ4 desaturase activity on the C22 7,10,13,16-docosatetraenoyl-CoA [ω6] and 7,20,13,16,19-docosapentaenoyl-CoA [ω3] by combining elongation in C24-CoA, C24 PUFA-CoA Δ6 desaturation and C24 Δ6 PUFA-CoA retroconversion into C22 Δ4 PUFA-CoA. This C24 to C22 retroconversion corresponds to a peroxisomal β-oxidizing cycle with two-carbon-chain cleavage. PUFA-CoA desaturation and elongation are catalyzed by microsomal proteins, elongation being also catalyzed by mitochondria.

6.1. Metabolic Intervention of ACOX1 in PUFA Retroconversion

In the scope of PUFA retroconversion, the C24 Δ6 PUFA-CoA requires import into peroxisomal matrix to which acyl-CoA β-oxidation enzymes belong. C24 Δ6 PUFA-CoAs are very long straight chain fatty acyl-CoAs. Transfer through peroxisomal membranes would be here assisted by ABCD2, which prefers unsaturated very long-chain fatty acids in contrast to ABCD1, the protein deficient in X-linked adrenoleukodystrophy, which preferentially acts on saturated VLCFA [63]. After import by ABCD2, the peroxisomal β-oxidation of C24 Δ6 PUFA-CoAs may proceed with peroxisomal acyl-CoA oxidase 1 (1st β-oxidation step), D-bifunctional protein (2nd and 3rd β-oxidation steps), and thiolases 1 and/or 2 (for the 4th and last step) [63]. This unique β-oxidation turn produces the C22 Δ4 PUFA-CoAs: DPA (4,7,10,13,16-docosapentaenoic acid [ω6]) and DHA (4,7,10,13,16,19-docosahexaenoic acid [ω3]) (DPA without other precision here refers to the n-6 DPA, the retroconversion product of TPA, and not to n-3 DPA, the product elongation of EPA).

7. Biosynthesis of Anti-Inflammatory Lipid Mediators from PUFAs “Retroconverted” by Peroxisomal ACOX1-Dependent β-Oxidation

As highlighted by Figure 4, in the absence of dietary DHA, though ACOX1 would not be needed for the formation of part of the resolvins, namely E series resolvins, it represents an essential step in the biosynthesis of the D-series resolvins, neuroprotectins, and maresins as a result of its key role in the retroconversion of PUFAs. On this light, it may be considered that the role of sepsis-mediated inhibition of ACOX1 might have been overlooked in the inflammatory challenge raised by sepsis in liver. In the same time, it may be asked whether protection of ACOX1 has not been also previously overlooked as an important feature in the anti-inflammatory potential conveyed by argan and olive oils.

The anti-inflammatory role of ACOX1 may be linked to its contribution to the yield of anti-inflammatory compounds. In this respect, DHA may be supplied by diet and endogenous biosynthesis. The last step in DHA biosynthesis is PUFA retroconversion which rests on a single peroxisomal ACOX1-initiated β-oxidation turn. Several works reviewed in [64] argue that resolvins, such as neuroprotectin D1 (NPD1), mediate anti-inflammatory and protective action of n-3 PUFAs in brain disorders. NPD1 is formed from DHA and reduces apoptosis in Alzheimer brain [65], whereas DHA and NPD1 lower transcript levels of the inflammatory gene products COX2 and NF-ΚB [66]. Protective effects of DHA and metabolites against chronic inflammations including cardiovascular disorders, asthma, rheumatoid arthritis, and inflammatory bowel diseases reviewed in [67] might also stress anti-inflammatory properties of ACOX1. In these studies, ACOX1 was bypassed by direct supplementation of its product (DHA) and derived metabolites (specialized proresolving mediators of the D series).

7.1. A Subtle Equilibrium between Desaturation, Elongation, and Oxidation of PUFA-CoA Esters

Desaturation and elongation of very long-chain PUFAs share in common with acyl-CoA oxidase 1 their action on CoA esters as substrates. It is likely that a subtle equilibrium exists between a given PUFA-CoA and its partition between the three fatty acid chain remodelling pathways and therefore this metabolic partition might be specific to the considered PUFA. The Δ6 desaturase involved prior the acyl-CoA oxidase 1-driven retroconversion corresponds to the fatty acid desaturase 2 (FADS2) gene product. Importantly, FADS2 is also responsible for the catalysis of a direct Δ4-desaturation of ARA and EPA directly to DPA and DHA, thus bypassing the retroconversion step (broken green arrow on Figure 4) [68] and complicating the metabolic partition mentioned above. On the other hand, in an animal model for acyl-CoA oxidase 1 gene KO, accumulation of very long-chain PUFAs were observed, corroborating the role of the peroxisomal oxidase in their retroconversion [69].

The recent advance in the biosynthesis of resolvins and recognition of their targets including various receptors among which GPCRs and also various microRNA (for a recent review, see [70]) has obviously heightened the interest in proteins intervening upstream formation of direct precursors of resolvins.

An important window to consider argan oil and ACOX1 as worthy regulators of inflammation perhaps lies in findings made in major disorders related to aging and known to involve inflammation. In this light, argan oil has been experimentally shown to be effective in blunting some of the features of diabetes and even in preventing chemically induced diabetes, displaying antihypertensive and antiproliferative properties, reducing in diabetic patients oxidation of LDL [7174]. ACOX1 was found to be increased by compounds including FGF19 (Fibroblast growth factor 19, a hormonal gut-derived peptide) and nordihydroguaiaretic acid (a Creosote bush metabolite), which have been shown to improve metabolic syndrome [75, 76]. Nordihydroguaiaretic acid is endowed with many biological properties including free radical scavenging, lipooxygenase inhibition, modulation of nuclear factor erythroid 2-related factor 2 (Nfr2)/antioxidant response element (ARE) signaling pathway, and cytoprotective and toxic properties towards normal and cancerous cells, respectively; this polyphenolic compound has also proven improvement in many disease conditions such as cancer, nephropathy, and neurodegenerative disorders (for valuable reviews, the reader may be kindly referred to [77, 78]). In fact, nordihydroguaiaretic acid has been shown to counteract major events, leading to metabolic syndrome and, in this context, to protect liver metabolism, fading high-fat-diet-induced hypertriglyceridemia and hepatic steatosis ([76] and references therein). Among changes induced by the phenol compound is increased transcript expression for ACOX1, which has been considered for its metabolic oxidizing role as regards to protection given by nordihydroguaiaretic acid. However, taking into account the known role of inflammation in the development of steatosis (for a review, see [79]), protection given by nordihydroguaiaretate-induced ACOX1 against steatosis might result from anti-inflammatory properties of ACOX1. FGF19 is upregulated by farnesoid X receptor (FXR) and is physiologically involved in carbohydrate, bile, and fatty acid metabolism (for a review, see [80]). It improves glucose and lipid homeostasis and tissue response to insulin, favours weight control and energy metabolism, and as a whole has a beneficial impact in diabetes, heart and kidney diseases, and in obesity and metabolic syndrome [80]. All these aging-related disorders face both metabolic impairment and inflammation, and therefore the fact that ACOX1 is one of the target proteins upregulated by FGF19 [75], might, not only metabolically but also by anti-inflammatory mechanisms, contribute to the health benefits attributed to FGF19. Recently, however, the therapeutic potential of stimulating FGF19 and related signaling has been shaded by showing mitogenic potential conveyed by part of FGF19 protein targets [75]. Additional understanding for the mechanisms specifically mediating metabolic effects and those specifically involved in proliferative effects of FGF19 is awaited in order to uncouple these effects to meet acceptable therapeutic development.

Aging is long known to reduce peroxisomal β-oxidation and to lower ACOX1 [81]. Interestingly also, aging is associated with an inflammation status notably resulting from a less efficacy of aging to resolve acute inflammation injuries [19]. This lowered effectiveness of the anti-inflammatory response has been shown to be associated with a drop in SPM formation [19]. Accordingly, age-related decline in resolving inflammation is corrected by providing SPM or one of their important precursors, DHA [19]. In aging and in several aging-related diseases, SPM deficiency and/or disease-improvement have been documented. Aging brain is protected by DHA and DHA-derived SPM (notably neuroprotectin D1) [34, 8285], which also improve outcome of brain ischemia-reperfusion episodes [8285]. DHA precursors, n-3 PUFAs, and DHA-derived SPM, neuroprotectin D1, improve mitochondrial dysfunction of senescent brain [86]. In Alzheimer’s disease and other degenerative disorders, DHA, SPM or SPM yield-enhancing strategies have proven efficacy in improving neuronal survival and inflammation-driven disease pathogenesis [34, 82, 83, 85, 8794]. Age-related retinal degeneration and vision disturbances have also been found to involve disturbances in DHA and SPM and to be protected by SPM through cell survival [82, 83, 85, 87, 89, 95]. Brain ischemia/reperfusion and stroke may be improved by SPM-driven survival signaling and reduction in infiltrating leucocytes [8284, 90]. Atherosclerosis has been also supported to be favourably modulated by SPM [96].

10. Anti-Inflammatory Roles of Peroxisomal ACOX1 versus Mitochondrial β-Oxidation

Most abundant fatty acids have a long and a straight carbon chain. When assessing the oxidation of these fatty acids as an energy-producing pathway, both mitochondrial and peroxisomal β-oxidation are considered, the former and the latter exhibiting major and minor contributions to overall fatty acid oxidation and the products of the latter being also potential substrates for the former. ACOX1, being the rate-limiting step in the peroxisomal oxidation of straight chain fatty acids, its activity is assayed to account for peroxisomal fatty acid oxidation capacity. Besides a limited role in energy production, ACOX1-driven peroxisomal β-oxidation, because taking place in the yield of potent anti-inflammatory metabolites, also plays a role in inflammation control as largely covered in this review. This role of ACOX1 remains, however, overlooked often in favor of its role in carbon-chain shortening and hence clearance of very long-chain fatty acids or in the contribution, even if minor, in energy production by ACOX1-driven peroxisomal β-oxidation. Whereas peroxisomal β-oxidation-driven protection against inflammation rests on generation of precursors for potent anti-inflammatory mediators, mitochondrial fatty acid oxidation-driven anti-inflammatory protection results from its capacity of removing proinflammatory compounds such as saturated fatty acids. These latter have been shown to promote insulin resistance, oxidative stress and oxidative damage and, in this respect, mitochondrial fatty acid oxidation meets anti-inflammatory function through avoidance of both ROS generation and lipotoxicity and through blunting of palmitate-induced proinflammatory cytokines, ER stress, and oxidative damage [97102]. On the opposite, mitochondrial fatty acid oxidation may also promote inflammation through inflammasome activation and synthesis of the proinflammatory IL 1β [103], making mitochondrial fatty acid oxidation, depending on the context, both inhibitor and stimulator of inflammation. In contrast to peroxisomal ACOX1-driven β-oxidation, mitochondrial fatty acid oxidation would not contribute to the synthesis of precursors for SPM. However, mitochondrial VLCAD (very long chain acyl-CoA dehydrogenase) and LCAD (long chain acyl-CoA dehydrogenase) KO mice have been described to exhibit tissue decrease in DHA (docosahexaenoic acid) levels [104], and whether this effect might result from a lack of contributing or regulatory effect of mitochondrial fatty acid oxidation or in turn interfering effect of mitochondrial enzyme deficiency through accumulating metabolites on DHA biosynthesis still remains to be elucidated. To our knowledge, SPM levels have still not been reported in peroxisomal and mitochondrial β-oxidation disorders.

Regarding the links between mitochondrial fatty acid oxidation and aging, age-dependent decrease in mitochondrial pathway [105], as well as either increase [106] or decrease [107] in CPT1 rate-limiting step have been reported. Age-dependent decrease of mitochondrial fatty acid oxidation has been shown to be dependent on age-related glutathione drop which also enhances ROS formation and promotes insulin resistance, these metabolic and signaling alterations being corrected by cysteine-based supplementations dedicated to restore intracellular glutathione stores [105]. Increased mitochondrial fatty acid oxidation might finally improve aging as for instance attested by its ability to alleviate age-related liver lipid accumulation [108].

11. Conclusion

Recent works on argan oil in prooxidative and inflammatory animal/human models provide a convergent sound support for the antioxidant/anti-inflammatory role of the peroxisomal enzyme, acyl-CoA oxidase type 1 (ACOX1). The model of LPS-driven toxicity and protection by argan oil has been transposed to model similarly aging inflammation also driven by reduced PGC1-α activity and also considered with a special emphasis on anti-inflammatory and hence antiaging key role of ACOX1. From the one hand, this view of ACOX1 is consistent with the key role played by peroxisomal ACOX1 in the production of precursor(s) for the synthesis of lipid mediators directly involved in the resolution of the inflammation process, and for this reason called resolvins. Resolvins and related compounds such as neuroprotectins and maresins are currently referred to as specialized proresolving mediators (SPM). On the other hand, aging and aging-related disorders are associated with reduced PGC1-α function, may be associated with reduced ACOX1 activity, lowered SPM levels, and delayed resolution of inflammation and may be improved by strategies rising ACOX1 (metabolic syndrome and diabetes) and SPM (brain and eye aging along with corresponding neurodegenerative disorders, atherosclerosis, and stroke). The strategical metabolic place occupied by ACOX1, upstream of SPM biosynthesis, along with ability of ACOX1 preservation/induction and of SPM to improve aging-related disorders and with the fact that aging is characterized by a drop in ACOX1 and SPM, all argue towards the view that ACOX1 represents a previously unsuspected and currently emerging antiaging protein.

Conflicts of Interest

The authors declare that there are no conflicts of interest.


This work was supported by the Action Intégrée of the Comité Mixte Inter-universitaire Franco-Marocain (CMIFM, AIMA/14/310, Campus France) from the PHC Volubilis/Toubkal program (No30293PA), Ministry of Foreign Affairs, The Centre National Pour la Recherche Scientifique et Technique (CNRST) Morocco, the Conseil Régional de Bourgogne (PARI2012:A324; PARI2013:B135; CPS0009) and the Ministère de l’enseignement et de la Recherche (crédits récurrents). The authors would like to acknowledge networking support by the COST (European Cooperation in Science and Technology) Action CA 16112 NutRedOx (Personalized Nutrition in aging society: redox control of major age-related diseases).


  1. J. H. Diaz, “Poisoning by herbs and plants: rapid toxidromic classification and diagnosis,” Wilderness & Environmental Medicine, vol. 27, no. 1, pp. 136–152, 2016. View at: Publisher Site | Google Scholar
  2. J. B. Lingrel, “The physiological significance of the cardiotonic steroid/ouabain-binding site of the Na,K-ATPase,” Annual Review of Physiology, vol. 72, no. 1, pp. 395–412, 2010. View at: Publisher Site | Google Scholar
  3. S. Man, W. Gao, C. Wei, and C. Liu, “Anticancer drugs from traditional toxic Chinese medicines,” Phytotherapy Research, vol. 26, no. 10, pp. 1449–1465, 2012. View at: Publisher Site | Google Scholar
  4. T. J. Lybbert, A. Aboudrare, D. Chaloud, N. Magnan, and M. Nash, “Booming markets for Moroccan argan oil appear to benefit some rural households while threatening the endemic argan forest,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 34, pp. 13963–13968, 2011. View at: Publisher Site | Google Scholar
  5. R. Ostan, M. C. Béné, L. Spazzafumo et al., “Impact of diet and nutraceutical supplementation on inflammation in elderly people. Results from the RISTOMED study, an open-label randomized control trial,” Clinical Nutrition, vol. 35, no. 4, pp. 812–818, 2016. View at: Publisher Site | Google Scholar
  6. R. El Kebbaj, P. Andreoletti, H. I. El Hajj et al., “Argan oil prevents down-regulation induced by endotoxin on liver fatty acid oxidation and gluconeogenesis and on peroxisome proliferator-activated receptor gamma coactivator-1α, (PGC-1α), peroxisome proliferator-activated receptor α (PPARα) and estrogen related receptor α (ERRα),” Biochimie Open, vol. 1, pp. 51–59, 2015. View at: Publisher Site | Google Scholar
  7. S. Ferdinandusse, S. Denis, P. A. Mooijer et al., “Identification of the peroxisomal beta-oxidation enzymes involved in the biosynthesis of docosahexaenoic acid,” Journal of Lipid Research, vol. 42, no. 12, pp. 1987–1995, 2001. View at: Google Scholar
  8. S. K. Orr and R. P. Bazinet, “The emerging role of docosahexaenoic acid in neuroinflammation,” Current Opinion in Investigational Drugs, vol. 9, no. 7, pp. 735–743, 2008. View at: Google Scholar
  9. C. N. Serhan, N. Chiang, J. Dalli, and B. D. Levy, “Lipid mediators in the resolution of inflammation,” Cold Spring Harbor Perspectives in Biology, vol. 7, no. 2, article a016311, 2014. View at: Publisher Site | Google Scholar
  10. R. El Kebbaj, S. El Kamouni, H. I. El Hajj et al., “Modulation of peroxisomes abundance by argan oil and lipopolysaccharides in acyl-CoA oxidase 1-deficient fibroblasts,” Health, vol. 5, no. 1, article 26522, 2013. View at: Publisher Site | Google Scholar
  11. H. Berrougui, M. Cloutier, M. Isabelle, and A. Khalil, “Phenolic-extract from argan oil (Argania spinosa L.) inhibits human low-density lipoprotein (LDL) oxidation and enhances cholesterol efflux from human THP-1 macrophages,” Atherosclerosis, vol. 184, no. 2, pp. 389–396, 2006. View at: Publisher Site | Google Scholar
  12. S. El Kamouni, R. El Kebbaj, P. Andreoletti et al., “Protective effect of argan and olive oils against LPS-induced oxidative stress and inflammation in mice livers,” International Journal of Molecular Sciences, vol. 18, no. 10, article 2181, 2017. View at: Publisher Site | Google Scholar
  13. L. Gurcel, L. Abrami, S. Girardin, J. Tschopp, and F. G. van der Goot, “Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival,” Cell, vol. 126, no. 6, pp. 1135–1145, 2006. View at: Publisher Site | Google Scholar
  14. K. Ishimoto, H. Nakamura, K. Tachibana et al., “Sterol-mediated regulation of human lipin 1 gene expression in hepatoblastoma cells,” Journal of Biological Chemistry, vol. 284, no. 33, pp. 22195–22205, 2009. View at: Publisher Site | Google Scholar
  15. M. C. Sugden, P. W. Caton, and M. J. Holness, “PPAR control: it’s SIRTainly as easy as PGC,” Journal of Endocrinology, vol. 204, no. 2, pp. 93–104, 2010. View at: Publisher Site | Google Scholar
  16. C. Zhang, A. A. Wendel, M. R. Keogh, T. E. Harris, J. Chen, and R. A. Coleman, “Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 5, pp. 1667–1672, 2012. View at: Publisher Site | Google Scholar
  17. G. S. Dhaunsi, C. D. Hanevold, and I. Singh, “Impairment of peroxisomal β-oxidation system by endotoxin treatment,” Molecular and Cellular Biochemistry, vol. 135, no. 2, pp. 187–193, 1994. View at: Publisher Site | Google Scholar
  18. J. Schilling, L. Lai, N. Sambandam, C. E. Dey, T. C. Leone, and D. P. Kelly, “Toll-like receptor-mediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-activated receptor γ coactivator-1 signaling,” Circulation: Heart Failure, vol. 4, no. 4, pp. 474–482, 2011. View at: Publisher Site | Google Scholar
  19. H. H. Arnardottir, J. Dalli, R. A. Colas, M. Shinohara, and C. N. Serhan, “Aging delays resolution of acute inflammation in mice: reprogramming the host response with novel nano-proresolving medicines,” The Journal of Immunology, vol. 193, no. 8, pp. 4235–4244, 2014. View at: Publisher Site | Google Scholar
  20. T. Wenz, “Mitochondria and PGC-1α in aging and age-associated diseases,” Journal of Aging Research, vol. 2011, Article ID 810619, 12 pages, 2011. View at: Publisher Site | Google Scholar
  21. M. E. Patti, A. J. Butte, S. Crunkhorn et al., “Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8466–8471, 2003. View at: Publisher Site | Google Scholar
  22. H. Zhang, S.-Y. Zhang, C. Jiang et al., “Intermedin/adrenomedullin 2 polypeptide promotes adipose tissue browning and reduces high-fat diet-induced obesity and insulin resistance in mice,” International Journal of Obesity, vol. 40, no. 5, pp. 852–860, 2016. View at: Publisher Site | Google Scholar
  23. A. O. Kadlec, D. S. Chabowski, K. Ait-Aissa et al., “PGC-1α (peroxisome proliferator–activated receptor γ coactivator 1-α) overexpression in coronary artery disease recruits NO and hydrogen peroxide during flow-mediated dilation and protects against increased intraluminal pressure,” Hypertension, vol. 70, no. 1, pp. 166–173, 2017. View at: Publisher Site | Google Scholar
  24. M. Sajan, B. Hansen, R. Ivey III et al., “Brain insulin signaling is increased in insulin-resistant states and decreases in FOXOs and PGC-1α and increases in Aβ1–40/42 and phospho-tau may abet Alzheimer development,” Diabetes, vol. 65, no. 7, pp. 1892–1903, 2016. View at: Publisher Site | Google Scholar
  25. G. Sweeney and J. Song, “The association between PGC-1α and Alzheimer’s disease,” Anatomy & Cell Biology, vol. 49, no. 1, pp. 1–6, 2016. View at: Publisher Site | Google Scholar
  26. H. Jiang, S. U. Kang, S. Zhang et al., “Adult conditional knockout of PGC-1α leads to loss of dopamine neurons,” eNeuro, vol. 3, no. 4, 2016. View at: Publisher Site | Google Scholar
  27. C. H. Ng, A. H. Basil, L. Hang et al., “Genetic or pharmacological activation of the Drosophila PGC-1α ortholog spargel rescues the disease phenotypes of genetic models of Parkinson’s disease,” Neurobiology of Aging, vol. 55, pp. 33–37, 2017. View at: Publisher Site | Google Scholar
  28. A. Siddiqui, A. Rane, S. Rajagopalan, S. J. Chinta, and J. K. Andersen, “Detrimental effects of oxidative losses in parkin activity in a model of sporadic Parkinson’s disease are attenuated by restoration of PGC1alpha,” Neurobiology of Disease, vol. 93, pp. 115–120, 2016. View at: Publisher Site | Google Scholar
  29. L. Cui, H. Jeong, F. Borovecki, C. N. Parkhurst, N. Tanese, and D. Krainc, “Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration,” Cell, vol. 127, no. 1, pp. 59–69, 2006. View at: Publisher Site | Google Scholar
  30. S. Jesse, H. Bayer, M. C. Alupei et al., “Ribosomal transcription is regulated by PGC-1alpha and disturbed in Huntington’s disease,” Scientific Reports, vol. 7, no. 1, p. 8513, 2017. View at: Publisher Site | Google Scholar
  31. P. Weydt, V. V. Pineda, A. E. Torrence et al., “Thermoregulatory and metabolic defects in Huntington’s disease transgenic mice implicate PGC-1α in Huntington’s disease neurodegeneration,” Cell Metabolism, vol. 4, no. 5, pp. 349–362, 2006. View at: Publisher Site | Google Scholar
  32. Ó. Fabregat-Andrés, F. Ridocci-Soriano, J. Estornell-Erill et al., “Blood PGC-1α concentration predicts myocardial salvage and ventricular remodeling after ST-segment elevation acute myocardial infarction,” Revista Española de Cardiología (English Edition), vol. 68, no. 5, pp. 408–416, 2015. View at: Publisher Site | Google Scholar
  33. H. F. Pei, J. N. Hou, F. P. Wei et al., “Melatonin attenuates postmyocardial infarction injury via increasing Tom70 expression,” Journal of Pineal Research, vol. 62, no. 1, article e12371, 2017. View at: Publisher Site | Google Scholar
  34. D. Sun and F. Yang, “Metformin improves cardiac function in mice with heart failure after myocardial infarction by regulating mitochondrial energy metabolism,” Biochemical and Biophysical Research Communications, vol. 486, no. 2, pp. 329–335, 2017. View at: Publisher Site | Google Scholar
  35. L. Tao, Y. Bei, S. Lin et al., “Exercise training protects against acute myocardial infarction via improving myocardial energy metabolism and mitochondrial biogenesis,” Cellular Physiology and Biochemistry, vol. 37, no. 1, pp. 162–175, 2015. View at: Publisher Site | Google Scholar
  36. Z. Wang, J. Ding, X. Luo et al., “Effect of allopurinol on myocardial energy metabolism in chronic heart failure rats after myocardial infarct,” International Heart Journal, vol. 57, no. 6, pp. 753–759, 2016. View at: Publisher Site | Google Scholar
  37. W. Yan, H. Zhang, P. Liu et al., “Impaired mitochondrial biogenesis due to dysfunctional adiponectin-AMPK-PGC-1α signaling contributing to increased vulnerability in diabetic heart,” Basic Research in Cardiology, vol. 108, no. 3, p. 329, 2013. View at: Publisher Site | Google Scholar
  38. S. Camandola and M. P. Mattson, “Brain metabolism in health, aging, and neurodegeneration,” EMBO Journal, vol. 36, no. 11, pp. 1474–1492, 2017. View at: Publisher Site | Google Scholar
  39. K. Róna-Vörös and P. Weydt, “The role of PGC-1α in the pathogenesis of neurodegenerative disorders,” Current Drug Targets, vol. 11, no. 10, pp. 1262–1269, 2010. View at: Publisher Site | Google Scholar
  40. S. M. Craige, S. Kröller-Schön, C. Li et al., “PGC-1α dictates endothelial function through regulation of eNOS expression,” Scientific Reports, vol. 6, no. 1, article 38210, 2016. View at: Publisher Site | Google Scholar
  41. A. O. Kadlec, D. S. Chabowski, K. Ait-Aissa, and D. D. Gutterman, “Role of PGC-1α in vascular regulation: implications for atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 36, no. 8, pp. 1467–1474, 2016. View at: Publisher Site | Google Scholar
  42. A. S. Ryan, G. Li, C. Hafer-Macko, and F. M. Ivey, “Resistive training and molecular regulators of vascular-metabolic risk in chronic stroke,” Journal of Stroke and Cerebrovascular Diseases, vol. 26, no. 5, pp. 962–968, 2017. View at: Publisher Site | Google Scholar
  43. Y. You, Y. Hou, X. Zhai et al., “Protective effects of PGC-1α via the mitochondrial pathway in rat brains after intracerebral hemorrhage,” Brain Research, vol. 1646, pp. 34–43, 2016. View at: Publisher Site | Google Scholar
  44. M. Cherkaoui-Malki, S. Surapureddi, H. I. El-Hajj, J. Vamecq, and P. Andreoletti, “Hepatic steatosis and peroxisomal fatty acid beta-oxidation,” Current Drug Metabolism, vol. 13, no. 10, pp. 1412–1421, 2012. View at: Publisher Site | Google Scholar
  45. R. J. A. Wanders, “Peroxisomes, lipid metabolism, and peroxisomal disorders,” Molecular Genetics and Metabolism, vol. 83, no. 1-2, pp. 16–27, 2004. View at: Publisher Site | Google Scholar
  46. S. Ferdinandusse, S. Denis, C. W. T. van Roermund et al., “A novel case of ACOX2 deficiency leads to recognition of a third human peroxisomal acyl-CoA oxidase,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1864, no. 3, pp. 952–958. View at: Publisher Site | Google Scholar
  47. C. Y. Fan, J. Pan, N. Usuda, A. V. Yeldandi, M. S. Rao, and J. K. Reddy, “Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor α natural ligand metabolism,” Journal of Biological Chemistry, vol. 273, no. 25, pp. 15639–15645, 1998. View at: Publisher Site | Google Scholar
  48. J. Huang, N. Viswakarma, S. Yu et al., “progressive endoplasmic reticulum stress contributes to hepatocarcinogenesis in fatty Acyl-CoA oxidase 1–deficient mice,” American Journal of Pathology, vol. 179, no. 2, pp. 703–713, 2011. View at: Publisher Site | Google Scholar
  49. A. Vluggens, P. Andreoletti, N. Viswakarma et al., “Functional significance of the two ACOX1 isoforms and their crosstalks with PPARα and RXRα,” Laboratory Investigation, vol. 90, no. 5, pp. 696–708, 2010. View at: Publisher Site | Google Scholar
  50. S. S. Lee, T. Pineau, J. Drago et al., “Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators,” Molecular and Cellular Biology, vol. 15, no. 6, pp. 3012–3022, 1995. View at: Publisher Site | Google Scholar
  51. F. S. Eichler, J. Q. Ren, M. Cossoy et al., “Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy?” Annals of Neurology, vol. 63, no. 6, pp. 729–742, 2008. View at: Publisher Site | Google Scholar
  52. H. I. El Hajj, A. Vluggens, P. Andreoletti et al., “The inflammatory response in acyl-CoA oxidase 1 deficiency (pseudoneonatal adrenoleukodystrophy),” Endocrinology, vol. 153, no. 6, pp. 2568–2575, 2012. View at: Publisher Site | Google Scholar
  53. A. S. Paintlia, A. G. Gilg, M. Khan, A. K. Singh, E. Barbosa, and I. Singh, “Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: implications for potential therapies,” Neurobiology of Disease, vol. 14, no. 3, pp. 425–439, 2003. View at: Publisher Site | Google Scholar
  54. H. Guillou, D. Zadravec, P. G. P. Martin, and A. Jacobsson, “The key roles of elongases and desaturases in mammalian fatty acid metabolism: insights from transgenic mice,” Progress in Lipid Research, vol. 49, no. 2, pp. 186–199, 2010. View at: Publisher Site | Google Scholar
  55. E. Christensen, B. Woldseth, T.-A. Hagve et al., “Peroxisomal β-oxidation of polyunsaturated long chain fatty acids in human fibroblasts. The polyunsaturated and the saturated long chain fatty acids are retroconverted by the same acyl-CoA oxidase,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 53, no. sup215, pp. 61–74, 1993. View at: Publisher Site | Google Scholar
  56. M. Grønn, E. Christensen, T. A. Hagve, and B. O. Christophersen, “Peroxisomal retroconversion of docosahexaenoic acid (22:6(n−3)) to eicosapentaenoic acid (20:5(n−3)) studied in isolated rat liver cells,” Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, vol. 1081, no. 1, pp. 85–91, 1991. View at: Publisher Site | Google Scholar
  57. T. A. Hagve and B. O. Christophersen, “Evidence for peroxisomal retroconversion of adrenic acid (22:4(n-6)) and docosahexaenoic acids (22:6(n-3)) in isolated liver cells,” Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, vol. 875, no. 2, pp. 165–173, 1986. View at: Publisher Site | Google Scholar
  58. S. A. Moore, E. Hurt, E. Yoder, H. Sprecher, and A. A. Spector, “Docosahexaenoic acid synthesis in human skin fibroblasts involves peroxisomal retroconversion of tetracosahexaenoic acid,” Journal of Lipid Research, vol. 36, no. 11, pp. 2433–2443, 1995. View at: Google Scholar
  59. H. M. Su, A. B. Moser, H. W. Moser, and P. A. Watkins, “Peroxisomal straight-chain acyl-CoA oxidase and D-bifunctional protein are essential for the retroconversion step in docosahexaenoic acid synthesis,” Journal of Biological Chemistry, vol. 276, no. 41, pp. 38115–38120, 2001. View at: Publisher Site | Google Scholar
  60. S. Nicosia and C. Patrono, “Eicosanoid biosynthesis and action: novel opportunities for pharmacological intervention,” FASEB Journal, vol. 3, no. 8, pp. 1941–1948, 1989. View at: Publisher Site | Google Scholar
  61. H. Tapiero, G. Nguyen Ba, P. Couvreur, and K. D. Tew, “Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies,” Biomedicine & Pharmacotherapy, vol. 56, no. 5, pp. 215–222, 2002. View at: Publisher Site | Google Scholar
  62. V. A. Ziboh, C. C. Miller, and Y. Cho, “Metabolism of polyunsaturated fatty acids by skin epidermal enzymes: generation of antiinflammatory and antiproliferative metabolites,” American Journal of Clinical Nutrition, vol. 71, 1 Supplement, pp. 361S–366S, 2000. View at: Google Scholar
  63. H. R. Waterham, S. Ferdinandusse, and R. J. A. Wanders, “Human disorders of peroxisome metabolism and biogenesis,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1863, no. 5, pp. 922–933, 2016. View at: Publisher Site | Google Scholar
  64. C. Boudrault, R. P. Bazinet, and D. W. L. Ma, “Experimental models and mechanisms underlying the protective effects of n-3 polyunsaturated fatty acids in Alzheimer’s disease,” The Journal of Nutritional Biochemistry, vol. 20, no. 1, pp. 1–10, 2009. View at: Publisher Site | Google Scholar
  65. W. J. Lukiw and N. G. Bazan, “Docosahexaenoic acid and the aging brain,” The Journal of Nutrition, vol. 138, no. 12, pp. 2510–2514, 2008. View at: Publisher Site | Google Scholar
  66. N. G. Bazan, “Survival signaling in retinal pigment epithelial cells in response to oxidative stress: significance in retinal degenerations,” Advances in Experimental Medicine and Biology, vol. 572, pp. 531–540, 2006. View at: Publisher Site | Google Scholar
  67. C. M. Yates, P. C. Calder, and G. Ed Rainger, “Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease,” Pharmacology & Therapeutics, vol. 141, no. 3, pp. 272–282, 2014. View at: Publisher Site | Google Scholar
  68. H. G. Park, W. J. Park, K. S. D. Kothapalli, and J. Thomas Brenna, “The fatty acid desaturase 2 (FADS2) gene product catalyzes Δ4 desaturation to yield n-3 docosahexaenoic acid and n-6 docosapentaenoic acid in human cells,” The FASEB Journal, vol. 29, no. 9, pp. 3911–3919, 2015. View at: Publisher Site | Google Scholar
  69. J. P. Infante, C. L. Tschanz, N. Shaw, A. L. Michaud, P. Lawrence, and J. T. Brenna, “Straight-chain acyl-CoA oxidase knockout mouse accumulates extremely long chain fatty acids from α-linolenic acid: evidence for runaway carousel-type enzyme kinetics in peroxisomal β-oxidation diseases,” Molecular Genetics and Metabolism, vol. 75, no. 2, pp. 108–119, 2002. View at: Publisher Site | Google Scholar
  70. Q. Qu, W. Xuan, and G. H. Fan, “Roles of resolvins in the resolution of acute inflammation,” Cell Biology International, vol. 39, no. 1, pp. 3–22, 2015. View at: Publisher Site | Google Scholar
  71. S. Bellahcen, Z. Hakkou, A. Ziyyat et al., “Antidiabetic and antihypertensive effect of virgin argan oil in model of neonatal streptozotocin-induced diabetic and l-nitroarginine methylester (l-NAME) hypertensive rats,” Journal of Complementary and Integrative Medicine, vol. 10, no. 1, 2013. View at: Publisher Site | Google Scholar
  72. S. Bellahcen, H. Mekhfi, A. Ziyyat et al., “Prevention of chemically induced diabetes mellitus in experimental animals by virgin argan oil,” Phytotherapy Research, vol. 26, no. 2, pp. 180–185, 2012. View at: Publisher Site | Google Scholar
  73. M. M. Ould Mohamedou, K. Zouirech, M. El Messal, M. S. El Kebbaj, A. Chraibi, and A. Adlouni, “Argan oil exerts an antiatherogenic effect by improving lipids and susceptibility of LDL to oxidation in type 2 diabetes patients,” International Journal of Endocrinology, vol. 2011, Article ID 747835, 8 pages, 2011. View at: Publisher Site | Google Scholar
  74. S. Samane, J. Noël, Z. Charrouf, H. Amarouch, and P. S. Haddad, “Insulin-sensitizing and anti-proliferative effects of Argania spinosa seed extracts,” Evidence-based Complementary and Alternative Medicine, vol. 3, no. 3, pp. 317–327, 2006. View at: Publisher Site | Google Scholar
  75. V. Massafra, A. Milona, H. R. Vos, B. M. T. Burgering, and S. W. C. van Mil, “Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation,” PLoS One, vol. 12, no. 2, article e0171185, 2017. View at: Publisher Site | Google Scholar
  76. H. Zhang, Y. Li, J. Hu et al., “Effect of creosote bush-derived NDGA on expression of genes involved in lipid metabolism in liver of high-fructose fed rats: relevance to NDGA amelioration of hypertriglyceridemia and hepatic steatosis,” PLoS One, vol. 10, no. 9, article e0138203, 2015. View at: Publisher Site | Google Scholar
  77. J. Hernández-Damián, A. C. Andérica-Romero, and J. Pedraza-Chaverri, “Paradoxical cellular effects and biological role of the multifaceted compound nordihydroguaiaretic acid,” Archiv der Pharmazie, vol. 347, no. 10, pp. 685–697, 2014. View at: Publisher Site | Google Scholar
  78. J. M. Lü, J. Nurko, S. M. Weakley et al., “Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: an update,” Medical Science Monitor, vol. 16, no. 5, pp. RA93–R100, 2010. View at: Google Scholar
  79. W. Peverill, L. Powell, and R. Skoien, “Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation,” International Journal of Molecular Sciences, vol. 15, no. 12, pp. 8591–8638, 2014. View at: Publisher Site | Google Scholar
  80. F. Zhang, L. Yu, X. Lin et al., “Minireview: roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases,” Molecular Endocrinology, vol. 29, no. 10, pp. 1400–1413, 2015. View at: Publisher Site | Google Scholar
  81. R. Périchon, J. M. Bourre, J. F. Kelly, and G. S. Roth, “The role of peroxisomes in aging,” Cellular and Molecular Life Sciences (CMLS), vol. 54, no. 7, pp. 641–652, 1998. View at: Publisher Site | Google Scholar
  82. N. G. Bazan, “Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection,” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 81, no. 2-3, pp. 205–211, 2009. View at: Publisher Site | Google Scholar
  83. N. G. Bazan, “Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease,” Journal of Lipid Research, vol. 50, Supplement, pp. S400–S405, 2009. View at: Publisher Site | Google Scholar
  84. F. Echeverría, R. Valenzuela, M. Catalina Hernandez-Rodas, and A. Valenzuela, “Docosahexaenoic acid (DHA), a fundamental fatty acid for the brain: new dietary sources,” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 124, pp. 1–10, 2017. View at: Publisher Site | Google Scholar
  85. P. K. Mukherjee, A. Chawla, M. S. Loayza, and N. G. Bazan, “Docosanoids are multifunctional regulators of neural cell integrity and fate: significance in aging and disease,” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 77, no. 5-6, pp. 233–238, 2007. View at: Publisher Site | Google Scholar
  86. S. Afshordel, S. Hagl, D. Werner et al., “Omega-3 polyunsaturated fatty acids improve mitochondrial dysfunction in brain aging – impact of Bcl-2 and NPD-1 like metabolites,” Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA), vol. 92, pp. 23–31, 2015. View at: Publisher Site | Google Scholar
  87. N. G. Bazan, M. F. Molina, and W. C. Gordon, “Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer’s, and other neurodegenerative diseases,” Annual Review of Nutrition, vol. 31, no. 1, pp. 321–351, 2011. View at: Publisher Site | Google Scholar
  88. M. Fiala, N. Terrando, and J. Dalli, “Specialized pro-resolving mediators from omega-3 fatty acids improve amyloid-β phagocytosis and regulate inflammation in patients with minor cognitive impairment,” Journal of Alzheimer's Disease, vol. 48, no. 2, pp. 293–301, 2015. View at: Publisher Site | Google Scholar
  89. W. J. Lukiw and N. G. Bazan, “Inflammatory, apoptotic, and survival gene signaling in Alzheimer’s disease. A review on the bioactivity of neuroprotectin D1 and apoptosis,” Molecular Neurobiology, vol. 42, no. 1, pp. 10–16, 2010. View at: Publisher Site | Google Scholar
  90. R. Palacios-Pelaez, W. J. Lukiw, and N. G. Bazan, “Omega-3 essential fatty acids modulate initiation and progression of neurodegenerative disease,” Molecular Neurobiology, vol. 41, no. 2-3, pp. 367–374, 2010. View at: Publisher Site | Google Scholar
  91. C. Zhang and N. G. Bazan, “Lipid-mediated cell signaling protects against injury and neurodegeneration’,” Journal of Nutrition, vol. 140, no. 4, pp. 858–863, 2010. View at: Publisher Site | Google Scholar
  92. Y. Zhao, S. Bhattacharjee, B. M. Jones, J. Hill, P. Dua, and W. J. Lukiw, “Regulation of neurotropic signaling by the inducible, NF-kB-sensitive miRNA-125b in Alzheimer’s disease (AD) and in primary human neuronal-glial (HNG) cells,” Molecular Neurobiology, vol. 50, no. 1, pp. 97–106, 2014. View at: Publisher Site | Google Scholar
  93. Y. Zhao, F. Calon, C. Julien et al., “Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in Alzheimer’s disease models,” PLoS One, vol. 6, no. 1, article e15816, 2011. View at: Publisher Site | Google Scholar
  94. M. Zhu, X. Wang, E. Hjorth et al., “Pro-resolving lipid mediators improve neuronal survival and increase Aβ42 phagocytosis,” Molecular Neurobiology, vol. 53, no. 4, pp. 2733–2749, 2016. View at: Publisher Site | Google Scholar
  95. N. G. Bazan, “Neurotrophins induce neuroprotective signaling in the retinal pigment epithelial cell by activating the synthesis nl of the anti-inflammatory and anti-apoptotic neuroprotectin D1,” Advances in Experimental Medicine and Biology, vol. 613, pp. 39–44, 2008. View at: Publisher Site | Google Scholar
  96. G. Fredman and I. Tabas, “Boosting inflammation resolution in atherosclerosis: the next frontier for therapy,” The American Journal of Patholology, vol. 187, no. 6, pp. 1211–1221, 2017. View at: Publisher Site | Google Scholar
  97. C. R. Bruce, A. J. Hoy, N. Turner et al., “Overexpression of carnitine palmitoyltransferase-1 in skeletal muscle is sufficient to enhance fatty acid oxidation and improve high-fat diet–induced insulin resistance,” Diabetes, vol. 58, no. 3, pp. 550–558, 2009. View at: Publisher Site | Google Scholar
  98. D. Namgaladze and B. Brüne, “Macrophage fatty acid oxidation and its roles in macrophage polarization and fatty acid-induced inflammation,” Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 1861, no. 11, pp. 1796–1807, 2016. View at: Publisher Site | Google Scholar
  99. D. Namgaladze, S. Lips, T. J. Leiker et al., “Inhibition of macrophage fatty acid β-oxidation exacerbates palmitate-induced inflammatory and endoplasmic reticulum stress responses,” Diabetologia, vol. 57, no. 5, pp. 1067–1077, 2014. View at: Publisher Site | Google Scholar
  100. M. I. Malandrino, R. Fucho, M. Weber et al., “Enhanced fatty acid oxidation in adipocytes and macrophages reduces lipid-induced triglyceride accumulation and inflammation,” American Journal of Physiology-Endocrinology and Metabolism, vol. 308, no. 9, pp. E756–E769, 2015. View at: Publisher Site | Google Scholar
  101. J. M. Orellana-Gavaldà, L. Herrero, M. I. Malandrino et al., “Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation,” Hepatology, vol. 53, no. 3, pp. 821–832, 2011. View at: Publisher Site | Google Scholar
  102. D. Sebastián, L. Herrero, D. Serra, G. Asins, and F. G. Hegardt, “CPT I overexpression protects L6E9 muscle cells from fatty acid-induced insulin resistance,” American Journal of Physiology-Endocrinology and Metabolism, vol. 292, no. 3, pp. E677–E686, 2007. View at: Publisher Site | Google Scholar
  103. J. S. Moon, K. Nakahira, K. P. Chung et al., “NOX4-dependent fatty acid oxidation promotes NLRP3 inflammasome activation in macrophages,” Nature Medicine, vol. 22, no. 9, pp. 1002–1012, 2016. View at: Publisher Site | Google Scholar
  104. S. M. Houten, S. Violante, F. V. Ventura, and R. J. A. Wanders, “The biochemistry and physiology of mitochondrial fatty acid β-oxidation and its genetic disorders,” Annual Review of Physiology, vol. 78, no. 1, pp. 23–44, 2016. View at: Publisher Site | Google Scholar
  105. D. Nguyen, S. L. Samson, V. T. Reddy, E. V. Gonzalez, and R. V. Sekhar, “Impaired mitochondrial fatty acid oxidation and insulin resistance in aging: novel protective role of glutathione,” Aging Cell, vol. 12, no. 3, pp. 415–425, 2013. View at: Publisher Site | Google Scholar
  106. L. Zhao, X. Zou, Z. Feng et al., “Evidence for association of mitochondrial metabolism alteration with lipid accumulation in aging rats,” Experimental Gerontology, vol. 56, pp. 3–12, 2014. View at: Publisher Site | Google Scholar
  107. R. H. Houtkooper, C. Argmann, S. M. Houten et al., “The metabolic footprint of aging in mice,” Science Reports, vol. 1, no. 1, p. 134, 2011. View at: Publisher Site | Google Scholar
  108. H. J. An, B. Lee, S. M. Kim et al., “A PPAR pan agonist, MHY2013 alleviates age-related hepatic lipid accumulation by promoting fatty acid oxidation and suppressing inflammation,” Biological & Pharmaceutical Bulletin, vol. 41, no. 1, pp. 29–35, 2018. View at: Publisher Site | Google Scholar

Copyright © 2018 Joseph Vamecq et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.